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Abstract
Aims/hypothesis Five clusters based on clinical characteristics have been suggested as diabetes subtypes: one autoimmune and
four subtypes of type 2 diabetes. In the current study we replicate and cross-validate these type 2 diabetes clusters in three large
cohorts using variables readily measured in the clinic.
Methods In three independent cohorts, in total 15,940 individuals were clustered based on age, BMI, HbA1c, random or fasting
C-peptide, and HDL-cholesterol. Clusters were cross-validated against the original clusters based on HOMA measures. In
addition, between cohorts, clusters were cross-validated by re-assigning people based on each cohort’s cluster centres. Finally,
we compared the time to insulin requirement for each cluster.
Results Five distinct type 2 diabetes clusters were identified and mapped back to the original four All New Diabetics in Scania
(ANDIS) clusters. Using C-peptide and HDL-cholesterol instead of HOMA2-B and HOMA2-IR, three of the clusters mapped
with high sensitivity (80.6–90.7%) to the previously identified severe insulin-deficient diabetes (SIDD), severe insulin-resistant
diabetes (SIRD) and mild obesity-related diabetes (MOD) clusters. The previously described ANDIS mild age-related diabetes
(MARD) cluster could be mapped to the two milder groups in our study: one characterised by high HDL-cholesterol (mild
diabetes with high HDL-cholesterol [MDH] cluster), and the other not having any extreme characteristic (mild diabetes [MD]).
When these two milder groups were combined, they mapped well to the previously labelled MARD cluster (sensitivity 79.1%).
In the cross-validation between cohorts, particularly the SIDD and MDH clusters cross-validated well, with sensitivities ranging
from 73.3% to 97.1%. SIRD and MD showed a lower sensitivity, ranging from 36.1% to 92.3%, where individuals shifted from
SIRD to MD and vice versa. People belonging to the SIDD cluster showed the fastest progression towards insulin requirement,
while the MDH cluster showed the slowest progression.
Conclusions/interpretation Clusters based on C-peptide instead of HOMA2 measures resemble those based on HOMA2
measures, especially for SIDD, SIRD andMOD. By adding HDL-cholesterol, the MARD cluster based upon HOMA2measures
resulted in the current clustering into two clusters, with one cluster having high HDL levels. Cross-validation between cohorts
showed generally a good resemblance between cohorts. Together, our results show that the clustering based on clinical variables
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readily measured in the clinic (age, HbA1c, HDL-cholesterol, BMI and C-peptide) results in informative clusters that are
representative of the original ANDIS clusters and stable across cohorts. Adding HDL-cholesterol to the clustering resulted in
the identification of a cluster with very slow glycaemic deterioration.
Keywords Clusters . C-peptide . Cross-validation . HDL-cholesterol . Type 2 diabetes
Abbreviations
ANDIS All New Diabetics in Scania
DCS Diabetes Care System
GoDARTS Genetics of Diabetes Audit and
Research Tayside Study
MARD Mild age-related diabetes
MD Mild diabetes
MDH Mild diabetes with high HDL-cholesterol
MOD Mild obesity-related diabetes
RHAPSODY Risk Assessment and ProgreSsiOn of
DIabetes
SIDD Severe insulin-deficient diabetes
SIRD Severe insulin-resistant diabetes
Introduction
A recent study stratified people with any form of diabetes into
five clusters based on six clinical variables, i.e. age, GAD
antibodies, BMI, HbA1c, insulin resistance (HOMA2-IR)
and beta cell function estimates (HOMA2-B) [1]. The five
clusters were characterised by autoimmunity (severe
autoimmune diabetes [SAID]), insulin deficiency (severe
insulin-deficient diabetes [SIDD]), insulin resistance (severe
insulin-resistant diabetes [SIRD]), high BMI (mild obesity-
related diabetes [MOD]) and the last without any extreme
characteristics other than high age (mild age-related diabetes
[MARD]) [1]. Clustering of people with diabetes has been
repeated successfully in several other studies based on these
variables in people of European descent and of other ethnici-
ties and based on different clinical measures [2–9]. In addi-
tion, the original and subsequent papers have shown that
people in different clusters have different risks for a number
of diabetes-related outcomes [1–4]. The autoimmunity and
insulin-deficient clusters were defined by high HbA1c at diag-
nosis, had higher risk for ketoacidosis and retinopathy [2, 7],
and progressed more rapidly onto insulin relative to the other
clusters [1]. Moreover, a recent study comprising multiple
cohorts enriched for cardiovascular risk assigned people to
the clusters identified by Ahlqvist et al [1] based on the
distance to the respective cluster centres. In this study, people
in the SIDD cluster showed higher risk of major adverse
cardiovascular events [5]. For the insulin-resistant cluster, a
higher frequency of non-alcoholic fatty liver disease has been
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observed and people in this group were at increased risk of
developing chronic kidney disease [1]. As HOMA2 calcula-
tions require fasting insulin or C-peptide and fasting glucose,
their measurement is not routine in clinical practice.
The aim of the current study is to perform a systematic
replication and cross-validation of clustering based on five
routine clinical variables in three large international cohorts
(Diabetes Care System [DCS], All New Diabetics in Scania
[ANDIS], Genetics of Diabetes Audit and Research Tayside
Study [GoDARTS]). In ANDIS, we directly compare the
current clusters with those identified in the original study [1].
Methods
Cohort descriptions
Data from 15,940 individuals with type 2 diabetes from three
cohorts, DCS (Netherlands), GoDARTS (Scotland) and ANDIS
(Sweden), were used in this cross-sectional study within the
RHAPSODY consortium. RHAPSODY (Risk Assessment and
ProgreSsiOn of Diabetes, https://imi-rhapsody.eu) is an
Innovative Medicine Initiative project and one of the aims is to
improve the segmentation of people with type 2 diabetes,
supporting the implementation of novel strategies for diabetes
prevention and treatment. Inclusion criteria for RHAPSODY
were age of diagnosis ≥35, clinical data available within
2 years after diagnosis, GAD negative, no missing data in one
of the five clinical measures used for clustering and the presence
of genome-wide association study (GWAS) data.
Hoorn DCS cohort The Hoorn DCS cohort is an open prospec-
tive cohort started in 1998 with currently over 14,000 individ-
uals with type 2 diabetes from the north-west part of the
Netherlands [10]. The study has been approved by the
Ethical Review Committee of the Vrije Universiteit
University Medical Center, Amsterdam. People visit DCS
annually to monitor their diabetes. During this visit, multiple
measurements are collected as part of routine care, including
anthropometric and laboratory measurements. Measurements
were used anonymously. Individuals were informed about the
use of their data and were offered an opt-out. All laboratory
measurements were done on samples taken in a fasted state.
HbA1c measurements were performed using the turbidimetric
inhibition immunoassay for haemolysed whole EDTA blood
(Cobas c501, Roche Diagnostics, Mannheim, Germany, run
CV 1.6%) [10]. HDL-cholesterol (mmol/l) was measured
enzymatically (Cobas c501, Roche Diagnostics). C-peptide
was measured on a DiaSorin Liaison (DiaSorin, Saluggia,
Italy). In total, 2953 individuals matched the inclusion criteria.
GoDARTS For clinical purposes, individuals with diabetes
mellitus from the Tayside region of Scotland (n = 391,274;
January 1996) were added to the Diabetes Audit and
Research Tayside Study (DARTS) register [11].
Retrospective and prospective longitudinal anonymised data
were collected, including data on prescribing and biochemis-
try and clinical data. All laboratory measurements were
measured in a non-fasted state. People with type 2 diabetes
were asked to participate in the Genetics of DARTS study
(GoDARTS), which currently includes over 10,000 individ-
uals with type 2 diabetes [11]. The GoDARTS study was
approved by the Tayside Medical Ethics Committee.
Informed consent was obtained from all participants. C-
peptide was measured on a DiaSorin Liaison. In total, 5509
individuals matched the inclusion criteria.
ANDIS The ANDIS cohort aims to recruit all people with inci-
dent diabetes within Scania County, Sweden. Recruitment
started in January 2008 until November 2016. People are
included in the study close to diagnosis, with a median of
40 days (IQR 12–99). All laboratory measurements were
measured in a fasted state. HbA1c measurements were obtain-
ed from the Clinical Chemistry database. C-peptide was deter-
mined with an electro-chemiluminescence immunoassay on a
Cobas e411 (Roche Diagnostics) or by a radioimmunoassay
(Human C-peptide radioimmunoassay; Linco, St Charles,
MO, USA; or Peninsula Laboratories, Belmont, CA, USA).
In total, 7478 individuals matched the inclusion criteria.
Statistical analysis
Clustering was performed on five risk factors for type 2 diabe-
tes progression [12]: age at first visit (years); BMI (kg/m2);
HbA1c (mmol/mol); HDL-cholesterol (mmol/l); and C-peptide
(nmol/l). C-peptide was included as a proxy of insulin resis-
tance and, to some extent, beta cell function (electronic supple-
mentary material [ESM] Table 1) in absence of fasting glucose
inGoDARTS (preventing the use of HOMA). HDL-cholesterol
levels were included as lower HDL-cholesterol has previously
been recognised as a risk factor for time to insulin requirement
[12]. Clustering was performed separately in each cohort and
stratified by sex. Clusters were defined based on k-means using
the kmeansruns function in the R package fpc (https://cran.r-
project.org/web/packages/fpc/index.html).The optimal number
of clusters was determined using the gap statistic across the
three cohorts [13], this being defined as the point where the
curve of the gap statistic vs the number of clusters flattened,
with little added value of increasing the number of clusters. The
stability of the clusters was assessed in two ways. The clusters
identified here in ANDIS using C-peptide instead of HOMA2
were compared with their previously published clusters based
on HOMA2 [1]. Second, identified clusters were cross-
validated between cohorts to assess their stability. For this,
individuals from cohort A were assigned to clusters based on
the cluster centres of each of the clusters identified in cohort B.
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This approach will quantify the probability that an individual in
cohort A will be assigned to the same cluster, but based on the
clusteringmodel for cohort B. Next, predicted clusters in cohort
A based on the clusters of cohort B were compared with the
‘real’ clusters of cohort A. This was done for each of the three
pairwise comparisons (DCS–GoDARTS, DCS–ANDIS,
GoDARTS–ANDIS). Agreement between clusters was
assessed based on the specificity and sensitivity.
Time to insulin requirement was defined as the period until
an individual started sustained (more than 6 months in dura-
tion) insulin treatment or required insulin, defined as ≥2
HbA1c measurements >69 mmol/mol (8.5%) at least 3 months
apart and when on ≥2 non-insulin glucose-lowering drugs.
Cox proportional hazard models were used where one cluster
was tested against the other clusters as a reference group in
each individual cohort. Thereafter, results were meta-analysed
using random effects meta-analysis using the metagen func-
tion from the meta package (https://cran.r-project.org/web/
packages/meta/index.html). Analyses were performed using
R statistics (version 3.6.2; https://www.r-project.org/).
Figures were produced using the R packages ggplot2 (v3.3.
0) (https://cran.r-project.org/web/packages/ggplot2/index.
html) and omicCircos (v1.22.0) (http://www.bioconductor.
org/packages/release/bioc/html/OmicCircos.html).
Results
Clustering in three large cohorts based on clinical
measures
In this cross-sectional study, 15,940 individuals from three
cohorts were included, for which baseline characteristics are
given in Table 1. The characteristics of the three cohorts were
generally comparable, with the majority male participants and
an average age of around 60 years. Individuals were clustered
based on age, BMI, HbA1c, C-peptide and HDL-cholesterol.
The optimal number of clusters was based on the gap statistic
across the three cohorts. In GoDARTS the optimal number of
clusters was five, with lower gap statistics from six onwards.
In DCS and ANDIS, the increase in gap statistic showed a
clear stabilisation after five clusters. Therefore, we considered
five the most optimal number of clusters (ESM Fig. 1a). The
first cluster comprised 13–17% of the individuals included. It
was characterised by high HbA1c, but, compared with the
other clusters, participants were younger with lower BMI, C-
peptide and HDL-cholesterol levels. When compared with the
original clusters in ANDIS [1], this cluster was most similar to
the SIDD cluster with a sensitivity (SEM) of 90.7% (CI
88.4%, 92.6%; Fig. 1, ESM Fig. 1b) [1]. Between 9% and
22% of individuals clustered to a cluster with high C-peptide
levels and age, but relatively lower HbA1c and HDL-
cholesterol levels, suggestive of insulin resistance. Indeed,
compared with the ANDIS clusters, this cluster resembled
most the SIRD cluster with an SEM of 92.4% (CI 89.7%,
94.6%; Fig. 1, ESM Fig. 1b) [1]. The third cluster comprised
participants with high BMI and the youngest age and relative-
ly lower levels of HbA1c and HDL-cholesterol. It was most
similar to the originally described MOD cluster with an SEM
of 80.6% (CI 78.4%, 82.7%) and comprised 18–23% of the
individuals included in the study. The fourth and fifth clusters
were most similar to the MARD cluster and showed a
combined sensitivity of 79.1% (CI 77.5%, 80.6%) against
the MARD cluster in ANDIS (Fig. 1, ESM Fig. 1b) [1]. The
fourth cluster, which was also the largest, encompassing 29–
35% of the individuals, showed no extreme characteristics and
was termed mild diabetes (MD). The fifth cluster was
characterised by higher age and HDL-cholesterol and was
termed mild diabetes with high HDL-cholesterol (MDH),
and comprised 16–19% of the individuals (Fig. 1). Between
male and female participants there were small differences in
characteristics, but the overall differences between clusters
were similar across both sexes (ESM Fig. 2).
Clusters cross-validate between the three cohorts
To assess the stability across cohorts, clusters were cross-
validated between cohorts. Clusters generally cross-validated
well between the three cohorts (ESM Fig. 3, ESM Table 2).
The SIDD andMDH clusters showed the highest sensitivity of
the five clusters identified, ranging from 85.6% (CI 83.5%,
87.6%) to 97.1% (CI 94.8%, 98.5%) in SIDD and from 73.3%
(CI 69.5%, 77.0%) to 92.9% (CI 91.3%, 94.3%) in MDH
(ESM Fig. 3, ESM Table 2). The SIRD and MD clusters
performed generally worst in terms of sensitivity, with sensi-
tivities ranging from 36.1% (CI 32.3%, 39.9%) to 92.3% (CI
90.1%, 94.2%) in SIRD and from 40.8% (CI 38.9%, 42.7%)
to 78.1% (CI 75.9%, 80.2%) in MD. Individuals clustered to
SIRDwere classified asMD and vice versa (ESMFig. 3, ESM
Table 2). The sensitivity of the MOD cluster ranged from
55.0% (CI 52.6%, 57.3%) to 93.2% (CI 91.5%, 94.7%).
Clusters are different in their progression to insulin
requirement
Next, we assessed differences between clusters in terms of
progression towards insulin initiation or requirement. As
expected, the SIDD cluster showed the fastest progression
(HR 3.40 [CI 1.72, 6.72]) compared with the other clusters
(Table 2, ESM Fig. 4). The SIRD group showed slower
progression (0.59 [0.46, 0.76]). The clustersMD andMDHalso
showed differences in their progression, where MDH showed
the slowest progression compared with the other clusters (0.44
[0.33, 0.59]), also slower than MD (0.81 [0.63, 1.06]).
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Discussion
Based on five clinical variables, people with type 2 diabetes
from three large European cohorts were assigned to five sepa-
rate clusters. Clusters were successfully cross-validated
against the clustering reported by Ahlqvist et al [1] but also
between cohorts included.
Even though we used slightly different variables for clus-
tering, i.e. C-peptide and HDL-cholesterol instead of HOMA2
measures [1], people were clustered largely to the same clus-
ters in a direct comparison with previously published clusters
in ANDIS. The insulin-deficient cluster (SIDD) was defined
by a high HbA1c, the insulin-resistant cluster (SIRD) by a high
C-peptide and the obese cluster (MOD) by a high BMI. The
previously identified MARD cluster [1] could be further
divided into two clusters of people with a low (MD cluster)
and a high HDL-cholesterol (MDH cluster). Including HDL-
cholesterol resulted in two clusters with mild characteristics,
where one had high HDL-cholesterol and one cluster had
generally a low HDL-cholesterol. A subset of the SIRD clus-
ter was classified asMD, which is most likely due to the use of
C-peptide and HDL-cholesterol instead of HOMA2measures.
Table 1 Characteristics of the
included individuals of the three
cohorts
Variable DCS GoDARTS ANDIS
n 2953 5509 7478
Male, % 55.9 56.3 60.1
Age, years 60.2 (53.1–66.9) 62.5 (54.5–70.0) 62.0 (54.0–69.8)
BMI, kg/m2 29.5 (26.7–33.2) 31.0 (27.6–35.1) 30.8 (26.9–34.0)
HbA1c, mmol/mol 49.7 (44.0–60.7) 58.0 (50.0–79.0) 62.3 (45.0–74.0)
HbA1c, % 6.7 (6.2–7.7) 7.5 (6.7–9.4) 7.9 (6.3–8.9)
C-peptide, nmol/l 1.0 (0.8–1.4) 1.9 (1.3–2.6) 1.3 (0.9–1.5)
HDL-cholesterol, mmol/l 1.2 (0.97–1.37) 1.1 (1.0–1.4) 1.2 (0.9–1.4)
LDL-cholesterol, mmol/l 3.0 (2.3–3.7) 2.7 (2.0–3.4) 3.2 (2.5–3.9)
Triacylglycerol, mmol/l 1.7 (1.2–2.3) 2.3 (1.6–3.3) 2.2 (1.2–2.4)
Glucose-lowering medication, % 61.5 19.0 59.6







































































































































































































g h i kj l

























































































































































































































































































Fig. 1 Characteristics of the clusters. (a–e, g–k, m–q) Characteristics of
the five clusters across the three cohorts; DCS (a–e), GoDARTS (g–k)
and ANDIS (m–q); x-axis, cluster; y-axis, age, BMI, HbA1c, HDL-
cholesterol and C-peptide. (f, l, r) Frequency and percentage of individ-
uals in each of the clusters; DCS (f), GoDARTS (l) and ANDIS (r)
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In addition to a comparison with the original ANDIS clus-
ters, in the current study we also cross-validated the clusters
across cohorts. Clusters cross-validated generally well and the
best sensitivity was observed in the SIDD and MDH clusters.
For SIRD and MD a lower sensitivity was observed.
Individuals that were classified in one cohort to SIRD or
MOD were classified as MD in a second cohort and vice
versa. The characteristics of particularly SIRD and MD are
very similar, with the sole difference being higher levels of
C-peptide in the SIRD cluster. This could explain the differ-
ence in classification in the two cohorts.
A limitation of the current study is that individuals in DCS
and GoDARTS were not clustered based on clinical data
collected at the time of diagnosis prior to treatment.
Different treatment regimens could have had an influence on
the clustering. However, it should be noted that ANDIS was
clustered based on data collected at the time of diagnosis and
in GoDARTS a smaller group was treated at baseline
compared with DCS. Therefore, treatment effects did not
seem to have a major influence on the clustering or the
cross-validation.
The progression towards insulin requirement of the identi-
fied clusters resembled that of the original clusters in ANDIS
[1]. The SIDD group showed the fastest progression, followed
by MOD. The SIRD group showed a generally slower
progression in our study. The MDH cluster that we addition-
ally identified showed the slowest progression of all clusters.
This shows that adding HDL-cholesterol to the clustering
allows the identification of a separate group among those with
mild diabetes with very low risk of glycaemic deterioration
towards insulin requirement.
Conclusion
In the current study, clusters were identified in three cohorts,
based on five different clinical characteristics. We show that
clusters based on random or fasted C-peptide instead of
HOMA2 measures resemble those based on HOMA2
measures. By adding HDL-cholesterol, we identified one
additional cluster with mild characteristics. Cross-validation
between cohorts showed that there was generally a good
resemblance between cohorts. Together, our results show that
the clustering is generally stable across cohorts, and also when
the clustering includes C-peptide instead of HOMAmeasures.
The novel MDH cluster represents a group of people with
mild diabetes and very low risk of glycaemic deterioration
towards insulin requirement.
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Table 2 Meta-analysis
results for time to insulin
requirement
Cluster HR (95%CI) p value
SIDD 3.40 (1.72, 6.72) 4.24×10−4
SIRD 0.59 (0.46, 0.76) 4.15×10−5
MOD 1.17 (0.64, 2.12) 0.61
MD 0.81 (0.63, 1.06) 0.12
MDH 0.44 (0.33, 0.59) 3.84×10−8
Each cluster was tested against the four
other clusters as reference group
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